1,786 reports of this reaction
4.0% of all LAMIVUDINE ORAL reports
#3 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #3 most commonly reported adverse reaction for LAMIVUDINE ORAL, manufactured by Apotex Corp.. There are 1,786 FDA adverse event reports linking LAMIVUDINE ORAL to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 4.0% of all 44,876 adverse event reports for this drug.
Patients taking LAMIVUDINE ORAL who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among LAMIVUDINE ORAL users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for LAMIVUDINE ORAL:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,786 FDA reports for LAMIVUDINE ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 4.0% of all adverse event reports for LAMIVUDINE ORAL, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking LAMIVUDINE ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.